Cargando…
Efficacy, Tolerability, and Retention of Antiseizure Medications in PRRT2-Associated Infantile Epilepsy
BACKGROUND AND OBJECTIVES: Pathogenic variants in PRRT2, encoding for the proline-rich transmembrane protein 2, were identified as the main cause of self-limiting sporadic and familial infantile epilepsy. Reported data on treatment response to antiseizure medications (ASMs) in defined monogenic epil...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9520344/ https://www.ncbi.nlm.nih.gov/pubmed/36187725 http://dx.doi.org/10.1212/NXG.0000000000200020 |
_version_ | 1784799603582828544 |
---|---|
author | Döring, Jan H. Saffari, Afshin Bast, Thomas Brockmann, Knut Ehrhardt, Laura Fazeli, Walid Janzarik, Wibke G. Klabunde-Cherwon, Annick Kluger, Gerhard Muhle, Hiltrud Pendziwiat, Manuela Møller, Rikke S. Platzer, Konrad Santos, Joana Larupa Schröter, Julian Hoffmann, Georg F. Kölker, Stefan Syrbe, Steffen |
author_facet | Döring, Jan H. Saffari, Afshin Bast, Thomas Brockmann, Knut Ehrhardt, Laura Fazeli, Walid Janzarik, Wibke G. Klabunde-Cherwon, Annick Kluger, Gerhard Muhle, Hiltrud Pendziwiat, Manuela Møller, Rikke S. Platzer, Konrad Santos, Joana Larupa Schröter, Julian Hoffmann, Georg F. Kölker, Stefan Syrbe, Steffen |
author_sort | Döring, Jan H. |
collection | PubMed |
description | BACKGROUND AND OBJECTIVES: Pathogenic variants in PRRT2, encoding for the proline-rich transmembrane protein 2, were identified as the main cause of self-limiting sporadic and familial infantile epilepsy. Reported data on treatment response to antiseizure medications (ASMs) in defined monogenic epilepsies are limited. The aim of this study was to evaluate the treatment response of ASMs in children with monogenic PRRT2-associated infantile epilepsy. METHODS: A multicenter, retrospective, cross-sectional cohort study was conducted according to the Strengthening the Reporting of Observational Studies in Epidemiology criteria. Inclusion criteria were occurrence of infantile seizures and genetic diagnosis of likely pathogenic/pathogenic PRRT2 variants. RESULTS: Treatment response data from 52 individuals with PRRT2-associated infantile epilepsy with a total of 79 treatments (defined as each use of an ASM in an individual) were analyzed. Ninety-six percent (50/52) of all individuals received ASMs. Levetiracetam (LEV), oxcarbazepine (OXC), valproate (VPA), and phenobarbital (PB) were most frequently administered. Sodium channel blockers were used in 22 individuals and resulted in seizure freedom in all but 1 child, who showed a reduction of more than 50% in seizure frequency. By contrast, treatment with LEV was associated with worsening of seizure activity in 2/25 (8%) treatments and no effect in 10/25 (40%) of treatments. LEV was rated significantly less effective also compared with VPA and PB. The retention rate for LEV was significantly lower compared with all aforementioned ASMs. No severe adverse events were reported, and no discontinuation of treatment was reported because of side effects. DISCUSSION: In conclusion, a favorable effect of most ASMs, especially sodium channel blockers such as carbamezepine and OXC, was observed, whereas the efficacy and the retention rate of LEV was lower in PRRT2-associated childhood epilepsy. Tolerability in these young children was good for all ASMs reported in the cohort. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that in individuals with PRRT2-associated infantile epilepsy, sodium channel blockers are associated with reduced seizure frequency but levetiracetam is not. |
format | Online Article Text |
id | pubmed-9520344 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Wolters Kluwer |
record_format | MEDLINE/PubMed |
spelling | pubmed-95203442022-09-29 Efficacy, Tolerability, and Retention of Antiseizure Medications in PRRT2-Associated Infantile Epilepsy Döring, Jan H. Saffari, Afshin Bast, Thomas Brockmann, Knut Ehrhardt, Laura Fazeli, Walid Janzarik, Wibke G. Klabunde-Cherwon, Annick Kluger, Gerhard Muhle, Hiltrud Pendziwiat, Manuela Møller, Rikke S. Platzer, Konrad Santos, Joana Larupa Schröter, Julian Hoffmann, Georg F. Kölker, Stefan Syrbe, Steffen Neurol Genet Research Article BACKGROUND AND OBJECTIVES: Pathogenic variants in PRRT2, encoding for the proline-rich transmembrane protein 2, were identified as the main cause of self-limiting sporadic and familial infantile epilepsy. Reported data on treatment response to antiseizure medications (ASMs) in defined monogenic epilepsies are limited. The aim of this study was to evaluate the treatment response of ASMs in children with monogenic PRRT2-associated infantile epilepsy. METHODS: A multicenter, retrospective, cross-sectional cohort study was conducted according to the Strengthening the Reporting of Observational Studies in Epidemiology criteria. Inclusion criteria were occurrence of infantile seizures and genetic diagnosis of likely pathogenic/pathogenic PRRT2 variants. RESULTS: Treatment response data from 52 individuals with PRRT2-associated infantile epilepsy with a total of 79 treatments (defined as each use of an ASM in an individual) were analyzed. Ninety-six percent (50/52) of all individuals received ASMs. Levetiracetam (LEV), oxcarbazepine (OXC), valproate (VPA), and phenobarbital (PB) were most frequently administered. Sodium channel blockers were used in 22 individuals and resulted in seizure freedom in all but 1 child, who showed a reduction of more than 50% in seizure frequency. By contrast, treatment with LEV was associated with worsening of seizure activity in 2/25 (8%) treatments and no effect in 10/25 (40%) of treatments. LEV was rated significantly less effective also compared with VPA and PB. The retention rate for LEV was significantly lower compared with all aforementioned ASMs. No severe adverse events were reported, and no discontinuation of treatment was reported because of side effects. DISCUSSION: In conclusion, a favorable effect of most ASMs, especially sodium channel blockers such as carbamezepine and OXC, was observed, whereas the efficacy and the retention rate of LEV was lower in PRRT2-associated childhood epilepsy. Tolerability in these young children was good for all ASMs reported in the cohort. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that in individuals with PRRT2-associated infantile epilepsy, sodium channel blockers are associated with reduced seizure frequency but levetiracetam is not. Wolters Kluwer 2022-09-28 /pmc/articles/PMC9520344/ /pubmed/36187725 http://dx.doi.org/10.1212/NXG.0000000000200020 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. |
spellingShingle | Research Article Döring, Jan H. Saffari, Afshin Bast, Thomas Brockmann, Knut Ehrhardt, Laura Fazeli, Walid Janzarik, Wibke G. Klabunde-Cherwon, Annick Kluger, Gerhard Muhle, Hiltrud Pendziwiat, Manuela Møller, Rikke S. Platzer, Konrad Santos, Joana Larupa Schröter, Julian Hoffmann, Georg F. Kölker, Stefan Syrbe, Steffen Efficacy, Tolerability, and Retention of Antiseizure Medications in PRRT2-Associated Infantile Epilepsy |
title | Efficacy, Tolerability, and Retention of Antiseizure Medications in PRRT2-Associated Infantile Epilepsy |
title_full | Efficacy, Tolerability, and Retention of Antiseizure Medications in PRRT2-Associated Infantile Epilepsy |
title_fullStr | Efficacy, Tolerability, and Retention of Antiseizure Medications in PRRT2-Associated Infantile Epilepsy |
title_full_unstemmed | Efficacy, Tolerability, and Retention of Antiseizure Medications in PRRT2-Associated Infantile Epilepsy |
title_short | Efficacy, Tolerability, and Retention of Antiseizure Medications in PRRT2-Associated Infantile Epilepsy |
title_sort | efficacy, tolerability, and retention of antiseizure medications in prrt2-associated infantile epilepsy |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9520344/ https://www.ncbi.nlm.nih.gov/pubmed/36187725 http://dx.doi.org/10.1212/NXG.0000000000200020 |
work_keys_str_mv | AT doringjanh efficacytolerabilityandretentionofantiseizuremedicationsinprrt2associatedinfantileepilepsy AT saffariafshin efficacytolerabilityandretentionofantiseizuremedicationsinprrt2associatedinfantileepilepsy AT bastthomas efficacytolerabilityandretentionofantiseizuremedicationsinprrt2associatedinfantileepilepsy AT brockmannknut efficacytolerabilityandretentionofantiseizuremedicationsinprrt2associatedinfantileepilepsy AT ehrhardtlaura efficacytolerabilityandretentionofantiseizuremedicationsinprrt2associatedinfantileepilepsy AT fazeliwalid efficacytolerabilityandretentionofantiseizuremedicationsinprrt2associatedinfantileepilepsy AT janzarikwibkeg efficacytolerabilityandretentionofantiseizuremedicationsinprrt2associatedinfantileepilepsy AT klabundecherwonannick efficacytolerabilityandretentionofantiseizuremedicationsinprrt2associatedinfantileepilepsy AT klugergerhard efficacytolerabilityandretentionofantiseizuremedicationsinprrt2associatedinfantileepilepsy AT muhlehiltrud efficacytolerabilityandretentionofantiseizuremedicationsinprrt2associatedinfantileepilepsy AT pendziwiatmanuela efficacytolerabilityandretentionofantiseizuremedicationsinprrt2associatedinfantileepilepsy AT møllerrikkes efficacytolerabilityandretentionofantiseizuremedicationsinprrt2associatedinfantileepilepsy AT platzerkonrad efficacytolerabilityandretentionofantiseizuremedicationsinprrt2associatedinfantileepilepsy AT santosjoanalarupa efficacytolerabilityandretentionofantiseizuremedicationsinprrt2associatedinfantileepilepsy AT schroterjulian efficacytolerabilityandretentionofantiseizuremedicationsinprrt2associatedinfantileepilepsy AT hoffmanngeorgf efficacytolerabilityandretentionofantiseizuremedicationsinprrt2associatedinfantileepilepsy AT kolkerstefan efficacytolerabilityandretentionofantiseizuremedicationsinprrt2associatedinfantileepilepsy AT syrbesteffen efficacytolerabilityandretentionofantiseizuremedicationsinprrt2associatedinfantileepilepsy |